ArticleScientific reports2025
An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypoxia-targeted BOLD MRI signal heterogeneity as a complementary metric for glioblastoma characterization: a pilot study.Journal of neuro-oncology · 2026Article
- The Intraoperative Golden Hour in Minimally Invasive Parafascicular Surgery for Brain Tumors.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioblastoma (GBM) displays marked intratumoral heterogeneity and high invasiveness, making en bloc resection difficult. In particular, total/subtotal resection is challenging for lesions near the diencephalon, midbrain, or brainstem or in motor areas, as damage to these sites can compromise postoperative function and reduce quality of life. Resection of GBM, especially deep-seated tumors, rarely achieves circumferential margins; pathological examination can only be performed on a portion of the tumor. Notably, traditional random intraoperative sampling introduces bias, limiting molecular profiling. The use of imaging-based biomarkers may mitigate this sampling bias, but critical molecular-region signatures remain undefined. In this study, we identified imaging parameters on structural magnetic resonance perfusion imaging to facilitate targeted sampling of representative glioma regions. Whole-exome sequencing of 29 samples from 6 patients revealed significant intratumoral heterogeneity in gene mutations across sampling sites, with edge regions showing the highest heterogeneity. Key cancer driver and drug-target gene mutations also exhibited heterogeneous spatial distributions. Critically, regions with elevated perfusion-weighted imaging cerebral blood volume (PWI-CBV) values demonstrated greater mutation heterogeneity and enrichment of key mutation events. To ensure comprehensive detection of heterogeneous mutations intraoperatively, we propose a three-site sampling strategy within high PWI-CBV regions. This approach may increase the accuracy and completeness of molecular pathological data, ultimately supporting personalized therapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.